VERAXA Biotech AG (NASDAQ: VRXA) Building a New Approach to Precision Cancer Therapy
VERAXA is developing antibody-based cancer therapies aimed at improving the therapeutic window of existing treatment modalities. Its proprietary BiTAC platform uses two complementary molecules that are designed to activate cytotoxic activity only when both recognize targets on the same tumor cell. The company is applying the BiTAC concept to both antibody-drug conjugates (“ADCs”) and T-cell engagers (“TCEs”), with an emphasis on solid tumors. With ADCs and bispecific antibodies attracting substantial investment, VERAXA is operating in oncology markets where technological differentiation can have significant strategic value. VERAXA Biotech (NASDAQ: VRXA) is developing a new generation of antibody-based cancer therapies at a…